Gilead seals generic Sovaldi deal with Natco, NICE rec for Harvoni in UK

India-based Natco Pharma will sell generic Sovaldi (sofosbuvir) and other hep C drugs in 91 countries. And Harvoni will come at a steep discount compared to the U.S. in the UK.

By Nicole Gray • March 3, 2015

Ousted Sanofi chief Chris Viebacher lands at PureTech

Viehbacher is joining the company, a Boston-based healthcare R&D firm, as a member of its Board of Directors.

By Nicole Gray • March 2, 2015

Pharmacyclics surges on news of potential sale to J&J, Novartis

It could become the biggest biotech deal since Sanofi/Genzyme.

By Nicole Gray • Feb. 26, 2015

Merck, MPP team up to provide low-cost HIV pediatric meds in poor countries

Merck's Isentress (raltegravir) is the only integrase inhibitor approved for pediatric treatment.

By Nicole Gray • Feb. 25, 2015

French government slams Sanofi over new CEO's pay

One government spokesperson called Olivier Brandicourt's pay package, which includes a $4.5 million entry bonus, "incomprehensible."

By Nicole Gray • Feb. 25, 2015

Shire keeps acquisition train rolling with $70M Meritage Pharma deal

Through the Meritage acquisition, Shire is gaining a phase 3 treatment for a rare GI disorder.

By Nicole Gray • Feb. 25, 2015

Platinum parachute? Allergan CEO Pyott could get $100M exit fee

Actavis has said that it will replace most of Allergan's executives with its own post-merger.  

By Nicole Gray • Feb. 25, 2015

Pfizer planning more layoffs in R&D

The company also says it will be adding positions in immuno-oncology and gene therapy as part of a new round of restructuring.  

By Sy Mukherjee • Feb. 24, 2015

Duchenne, orphan drug maker PTC Therapeutics fielding takeover bids

According to an exclusive report from Reuters.

By Nicole Gray • Feb. 24, 2015

Cellectis files $115M IPO to fund unique CAR-T program

The CAR-T competition is heating up as Cellectis, based in Paris, brings a new approach to cancer immunotherapy using allogeneic treatments.

By Nicole Gray • Feb. 22, 2015

UPDATE: Valeant to buy Salix for $10.1B, cleared for $495M Dendreon buyout

And company CEO Michael Pearson said on Monday that smaller deals are still on the horizon.

By Sy Mukherjee • Feb. 20, 2015

UPDATE: Bayer HealthCare chief Brandicourt named Sanofi's next CEO

Four months after the ouster of former Sanofi CEO Chris Viehbacher, the company has decided to hire a pharma veteran. But just how much power will Brandicourt have?

By Nicole Gray , Sy Mukherjee • Feb. 19, 2015

The more, the merrier? Endo also pursuing Salix Pharma bid

On top of Valeant and Shire.

By Nicole Gray • Feb. 18, 2015

Can AZ finally solidify a deal for its anti-infectives unit?

For more than a year, AstraZeneca has been shopping a partnership deal for its anti-infectives unit. But there don't seem to be any takers—and the clock is ticking.

By Nicole Gray • Feb. 17, 2015

Valeant arranges financing for potential Salix Pharma bid

Now that Valeant has secured sufficient funding, it is better positioned to make a bid for gastroenterology-focused Salix Pharmaceuticals.

By Nicole Gray • Feb. 13, 2015

Indian pharma giants scuffle to snap up injectables maker Claris

Claris Lifesciences, based in Ahmedabad, focuses on generic sterile injectables—an area where demand currently outweighs supply.

By Nicole Gray • Feb. 13, 2015

Shire raises 2015 forecast on NPS acquisition

After striking a $5.2 billion deal for NJ-based NPS Pharma last month, Shire, which is based in Ireland, is forecasting growth in the 5% to 9% range.

By Nicole Gray • Feb. 12, 2015

Hospira CEO's golden parachute for Pfizer deal: $80 million

That includes stock options and tax payments.

By Sy Mukherjee • Feb. 12, 2015

GSK broadens vax portfolio with $190M GlycoVaxyn deal

This is on top of a $5.25 billion vaccine deal with Novartis.

By Nicole Gray • Feb. 12, 2015

Gilead to open London HQ, double UK workforce

The new HQ will cost $19.6 million. 

By Sy Mukherjee • Feb. 10, 2015

BIO survey finds more series A VC funding for fewer recipients

A venture capital funding survey conducted by the Biotechnology Industry Organization (BIO) revealed several paradoxes, but also encouraging insight into how series A funding is driving start-ups.

By Nicole Gray • Feb. 10, 2015

Pfizer may still be hungry after Hospira deal

Pfizer's recent $15 billion acquisition of Hospira has led to speculation that the company is on the acquisition hunt.

By Nicole Gray • Feb. 9, 2015

Isis earns $10 million milestone from Biogen Idec

If ever there were a productive partnership, Biogen Idec and Isis Pharma have it.

By Nicole Gray • Feb. 6, 2015

NY Attorney General nabs price reduction for heroin-fighting naloxone

The price of naloxone, which is used as a heroin antidote, doubled last fall, putting tremendous pressure on health officials who treat addicts.

By Nicole Gray • Feb. 6, 2015

Trans-Pacific Partnership trade talks fail to resolve patent & IP issues

The U.S. wants 12 years of protection. Emerging markets want about seven. Can negotiators bridge the gap?

By Nicole Gray • Feb. 5, 2015